AR073263A1 - Derivados de piridina y su uso en diagnostico de imagenes mediante pet - Google Patents
Derivados de piridina y su uso en diagnostico de imagenes mediante petInfo
- Publication number
- AR073263A1 AR073263A1 ARP090102997A ARP090102997A AR073263A1 AR 073263 A1 AR073263 A1 AR 073263A1 AR P090102997 A ARP090102997 A AR P090102997A AR P090102997 A ARP090102997 A AR P090102997A AR 073263 A1 AR073263 A1 AR 073263A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- aryl
- substituted aryl
- group
- compositions
- Prior art date
Links
- 238000003745 diagnosis Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 8
- 125000003107 substituted aryl group Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- -1 [18F] fluoro Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 238000002059 diagnostic imaging Methods 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 238000002372 labelling Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002600 positron emission tomography Methods 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Radiology & Medical Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nuclear Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuestos adecuados para marcar o ya marcados con 18F, con métodos para preparar tales compuestos, con composiciones que comprenden dichos compuestos, con conjuntos de elementos que comprenden dichos compuestos o composiciones y con los usos de dichos compuestos, composiciones o conjuntos de elementos en terapias y para diagnostico por imágenes mediante tomografía de emision de positrones (PET). Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1) donde: R1 y R2 se seleccionan en forma independiente e individual, en cada instancia, entre el grupo que consiste de (G3)arilo, (G3)arilo sustituido, (G3-alquil C1-8)arilo, (G3-alcoxi C1-8)arilo, (G3-alquinil C2-8)arilo, (G3-alquenil C2-8)arilo, (G3-alquil C1-8)arilo sustituido, (G3-alcoxi C1-8)arilo sustituido, (G3-alquinil C2-8)arilo sustituido y (G3-alquenil C2-8)arilo sustituido; G1, G2 y G3 se seleccionan en forma independiente e individual, en cada instancia, entre el grupo que consiste de hidrogeno y L, con la condicion de que los compuestos de formula (1) contienen exactamente un L; L se selecciona entre el grupo que consiste de R3, [18F] fluoro y [19F] fluoro; R3 es un grupo saliente; donde n es un entero entre 0 y 6; incluyendo todas las formas isoméricas de dicho compuesto, incluyendo pero sin limitarse a enantiomeros y diastereoisomeros así como también mezclas racémicas, y cualquier sal, éster, amida, complejo o prodroga aceptable farmacéuticamente del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08161903 | 2008-08-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR073263A1 true AR073263A1 (es) | 2010-10-28 |
Family
ID=41198601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102997A AR073263A1 (es) | 2008-08-06 | 2009-08-05 | Derivados de piridina y su uso en diagnostico de imagenes mediante pet |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20110200535A1 (es) |
| EP (1) | EP2321279B1 (es) |
| JP (1) | JP2011529929A (es) |
| KR (1) | KR20110041559A (es) |
| CN (1) | CN102112448B (es) |
| AR (1) | AR073263A1 (es) |
| AU (1) | AU2009278279B2 (es) |
| BR (1) | BRPI0917099A2 (es) |
| CA (1) | CA2733105A1 (es) |
| CL (1) | CL2011000237A1 (es) |
| CO (1) | CO6351715A2 (es) |
| CR (1) | CR20110064A (es) |
| DO (1) | DOP2011000046A (es) |
| EA (1) | EA018650B1 (es) |
| EC (1) | ECSP11010808A (es) |
| IL (1) | IL210597A0 (es) |
| MX (1) | MX2011001406A (es) |
| NZ (1) | NZ590923A (es) |
| PE (1) | PE20110226A1 (es) |
| SV (1) | SV2011003830A (es) |
| TW (1) | TW201010734A (es) |
| UY (1) | UY32037A (es) |
| WO (2) | WO2010015340A1 (es) |
| ZA (1) | ZA201101700B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2804801T3 (es) | 2006-12-26 | 2021-02-09 | Lantheus Medical Imaging Inc | Ligandos para la formación de imágenes de la inervación cardíaca |
| WO2010015340A1 (en) * | 2008-08-06 | 2010-02-11 | Bayer Schering Pharma Aktiengesellschaft | Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment |
| GB0904715D0 (en) | 2009-03-19 | 2009-05-06 | Ge Healthcare Ltd | Aryloxyanilide derivataives |
| WO2011110488A1 (en) * | 2010-03-09 | 2011-09-15 | Bayer Pharma Aktiengesellschaft | A novel pet imaging agent of amyloid plaques and its precursor |
| KR20170042373A (ko) * | 2010-05-11 | 2017-04-18 | 랜티우스 메디컬 이메징, 인크. | 영상화제의 합성 및 사용을 위한 조성물, 방법 및 시스템 |
| CA2799381A1 (en) | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Male contraceptive compositions and methods of use |
| MX373121B (es) | 2010-05-14 | 2020-04-30 | Dana Farber Cancer Inst Inc | Composiciones y metodos para el tratamiento de leucemia. |
| US8981083B2 (en) | 2010-05-14 | 2015-03-17 | Dana Farber Cancer Institute, Inc. | Compositions and methods for treating neoplasia, inflammatory disease and other disorders |
| EP3567029A1 (en) | 2011-09-09 | 2019-11-13 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
| BR112016001457A2 (pt) | 2013-07-25 | 2017-08-29 | Dana Farber Cancer Inst Inc | Inibidores de fatores de transcrição e usos dos mesmos |
| KR20160072261A (ko) | 2013-11-08 | 2016-06-22 | 다나-파버 캔서 인스티튜트 인크. | 브로모도메인 및 엑스트라-말단 (bet) 단백질 저해제를 이용한 암 치료를 위한 조합 요법 |
| WO2015117087A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| MX2016009974A (es) | 2014-01-31 | 2016-10-31 | Dana Farber Cancer Inst Inc | Derivados de diaminopirimidina bencensulfona y sus usos. |
| RU2722179C2 (ru) | 2014-02-28 | 2020-05-28 | Тэнша Терапеутикс, Инк. | Лечение состояний, ассоциированных с гиперинсулинемией |
| WO2016022970A1 (en) | 2014-08-08 | 2016-02-11 | Dana-Farber Cancer Institute, Inc. | Dihydropteridinone derivatives and uses thereof |
| EP3177626A4 (en) | 2014-08-08 | 2017-12-27 | Dana Farber Cancer Institute, Inc. | Diazepane derivatives and uses thereof |
| UA122130C2 (uk) | 2014-10-27 | 2020-09-25 | Тенша Терапеутікс, Інк. | Інгібітори бромодомену |
| US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| JP2018526424A (ja) | 2015-09-11 | 2018-09-13 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | アセトアミドチエノトリアゾロジアゼピンおよびこれらの使用 |
| US11306105B2 (en) | 2015-09-11 | 2022-04-19 | Dana-Farber Cancer Institute, Inc. | Cyano thienotriazolodiazepines and uses thereof |
| CR20180336A (es) | 2015-11-25 | 2018-08-06 | Dana Farber Cancer Inst Inc | Inhibidores de bromodominio bivalentes y usos de los mismos |
| CN105541931B (zh) * | 2016-01-07 | 2018-08-17 | 江西师范大学 | 一种氟代糖苷衍生物及其制备方法 |
| EP3717025B1 (en) * | 2017-12-01 | 2021-11-03 | UCB Biopharma SRL | Imaging agents |
| CN111039853B (zh) * | 2019-12-26 | 2023-02-14 | 安徽大学 | 一种可用于光声成像和光热治疗的铁配合物及其制备方法和用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1004573B1 (en) * | 1997-08-04 | 2002-10-30 | Taisho Pharmaceutical Co., Ltd | Aryloxyaniline derivatives |
| JP2000001476A (ja) * | 1998-06-15 | 2000-01-07 | Taisho Pharmaceut Co Ltd | アリールオキシ含窒素アリールアミン誘導体 |
| JP2004231647A (ja) * | 2003-01-10 | 2004-08-19 | Natl Inst Of Radiological Sciences | フェニルオキシアニリン誘導体 |
| US6870069B2 (en) * | 2003-01-10 | 2005-03-22 | National Institute Of Radiological Sciences | Phenyloxyaniline derivatives |
| GB0329716D0 (en) * | 2003-12-23 | 2004-01-28 | Amersham Plc | Radical trap |
| GB0407952D0 (en) * | 2004-04-08 | 2004-05-12 | Amersham Plc | Fluoridation method |
| US8644910B2 (en) * | 2005-07-19 | 2014-02-04 | Biosensors International Group, Ltd. | Imaging protocols |
| DE102005055524B4 (de) * | 2005-11-22 | 2013-02-07 | BEGO Bremer Goldschlägerei Wilh. Herbst GmbH & Co. KG | Verfahren, Vorrichtung und System zur Herstellung eines keramischen Formkörpers |
| WO2007060517A1 (en) * | 2005-11-22 | 2007-05-31 | Ge Healthcare Limited | 18f-labeled daa analogues and methods of labeling these analogues as positron emission tomography (pet) tracers for imaging peripheral benzodiazepine receptors |
| GB0525949D0 (en) * | 2005-12-21 | 2006-02-01 | Hammersmith Imanet Ltd | Pet radiotracers |
| KR101554366B1 (ko) * | 2006-06-21 | 2015-09-18 | 지이 헬쓰케어 리미티드 | 방사성 의약품 |
| WO2010015340A1 (en) * | 2008-08-06 | 2010-02-11 | Bayer Schering Pharma Aktiengesellschaft | Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment |
-
2009
- 2009-07-25 WO PCT/EP2009/005399 patent/WO2010015340A1/en not_active Ceased
- 2009-08-03 TW TW098126076A patent/TW201010734A/zh unknown
- 2009-08-05 UY UY0001032037A patent/UY32037A/es not_active Application Discontinuation
- 2009-08-05 EP EP09777654.6A patent/EP2321279B1/en not_active Not-in-force
- 2009-08-05 JP JP2011521474A patent/JP2011529929A/ja active Pending
- 2009-08-05 AU AU2009278279A patent/AU2009278279B2/en not_active Ceased
- 2009-08-05 CA CA2733105A patent/CA2733105A1/en not_active Abandoned
- 2009-08-05 CN CN200980130507.6A patent/CN102112448B/zh not_active Expired - Fee Related
- 2009-08-05 EA EA201100301A patent/EA018650B1/ru not_active IP Right Cessation
- 2009-08-05 US US13/057,215 patent/US20110200535A1/en not_active Abandoned
- 2009-08-05 KR KR1020117005160A patent/KR20110041559A/ko not_active Ceased
- 2009-08-05 MX MX2011001406A patent/MX2011001406A/es not_active Application Discontinuation
- 2009-08-05 AR ARP090102997A patent/AR073263A1/es not_active Application Discontinuation
- 2009-08-05 WO PCT/EP2009/005651 patent/WO2010015387A1/en not_active Ceased
- 2009-08-05 PE PE2011000123A patent/PE20110226A1/es not_active Application Discontinuation
- 2009-08-05 BR BRPI0917099A patent/BRPI0917099A2/pt not_active IP Right Cessation
- 2009-08-05 NZ NZ590923A patent/NZ590923A/xx not_active IP Right Cessation
-
2011
- 2011-01-12 IL IL210597A patent/IL210597A0/en unknown
- 2011-02-04 EC EC2011010808A patent/ECSP11010808A/es unknown
- 2011-02-04 CR CR20110064A patent/CR20110064A/es unknown
- 2011-02-04 CO CO11013225A patent/CO6351715A2/es not_active Application Discontinuation
- 2011-02-04 SV SV2011003830A patent/SV2011003830A/es not_active Application Discontinuation
- 2011-02-04 DO DO2011000046A patent/DOP2011000046A/es unknown
- 2011-02-04 CL CL2011000237A patent/CL2011000237A1/es unknown
- 2011-03-04 ZA ZA2011/01700A patent/ZA201101700B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110041559A (ko) | 2011-04-21 |
| JP2011529929A (ja) | 2011-12-15 |
| EP2321279A1 (en) | 2011-05-18 |
| ZA201101700B (en) | 2014-08-27 |
| BRPI0917099A2 (pt) | 2016-02-16 |
| WO2010015387A1 (en) | 2010-02-11 |
| CO6351715A2 (es) | 2011-12-20 |
| CN102112448A (zh) | 2011-06-29 |
| DOP2011000046A (es) | 2011-02-28 |
| WO2010015340A1 (en) | 2010-02-11 |
| TW201010734A (en) | 2010-03-16 |
| ECSP11010808A (es) | 2011-03-31 |
| EP2321279B1 (en) | 2014-07-02 |
| AU2009278279B2 (en) | 2014-04-17 |
| CA2733105A1 (en) | 2010-02-11 |
| EA018650B1 (ru) | 2013-09-30 |
| CL2011000237A1 (es) | 2011-07-29 |
| IL210597A0 (en) | 2011-03-31 |
| NZ590923A (en) | 2012-12-21 |
| CN102112448B (zh) | 2014-08-06 |
| US20110200535A1 (en) | 2011-08-18 |
| AU2009278279A1 (en) | 2010-02-11 |
| UY32037A (es) | 2010-03-26 |
| EA201100301A1 (ru) | 2011-12-30 |
| CR20110064A (es) | 2011-03-30 |
| MX2011001406A (es) | 2011-03-21 |
| SV2011003830A (es) | 2011-05-20 |
| PE20110226A1 (es) | 2011-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR073263A1 (es) | Derivados de piridina y su uso en diagnostico de imagenes mediante pet | |
| PE20141160A1 (es) | Metodos para preparar analogos nucleotidicos antivirales | |
| UY30112A1 (es) | Nuevos benzotiazoles sustitidos por heteroarilo | |
| GT201300207A (es) | Derivados de heteroarilo como moduladores de nachr alfa 7 | |
| AR071054A1 (es) | Compuestos para usar en la formacion de imagenes el diagnostico y/o el tratamiento de enfermedades del sistema nervioso central o de tumores, metodos de preparacion, composiciones farmaceuticas, usos y metodos de deteccion de monoamina oxidasa. | |
| CO6761397A2 (es) | Métodos para preparar glicoesfingolípidos y usos de los mismos | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| CO6251367A2 (es) | Derivados de 6-amino-5-aril piridina-2il-carboxamida | |
| NI201400023A (es) | Derivados de pirrolopirimidina y purina | |
| MX346145B (es) | Composición de sistema de suministro de arnsi in vivo basado en péptidos. | |
| ECSP12011857A (es) | Compuestos de dióxido de iminotiadiazina como inhibidores de bace, composiciones, y su uso | |
| CR10654A (es) | Agentes que comprenden compuestos marcados con 18f y metodos relacionados | |
| CL2013001558A1 (es) | El uso de compuestos moduladores o agonistas de los receptores de s1p para disminuir la frecuencia cardiaca en aproximadamente 2 latidos/minuto; metodo para aminorar, prevenir o limitar un efecto cronotropico negativo; un kit farmaceutico. | |
| CO6300898A2 (es) | Sales y polimorfos de 9-(2,2-dimetil-propil-aminometil)-minociclina | |
| ECSP15012804A (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
| ECSP13012596A (es) | Proceso de elaboración para derivados de pirimidina | |
| ECSP14013215A (es) | Compuestos novedosos | |
| PE20091723A1 (es) | Derivados de acido l-glutamico marcado con [18 f] y l-glutamina marcada con [18f] | |
| SG194761A1 (en) | Radiolabeled amino acids for diagnostic imaging | |
| CO2021013166A2 (es) | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria | |
| AR074593A1 (es) | Benzotiazol amidas para la deteccion del peptido beta amiloide | |
| ES2584556T3 (es) | Composiciones novedosas que contienen carbodiimida, un procedimiento para su preparación y su uso | |
| AR086803A1 (es) | Derivados de oxazetidinas, composiciones farmaceuticas y cosmeticas que los contienen y uso de los mismos para tratar enfermedades dermatologicas fundamentalmente, y del aparato respiratorio, digestivo y cardiovascular, entre otras | |
| ES2528370T3 (es) | Derivados (3-metilpirrolidín-3-il)metil-piridinil éter y su uso como antagonistas del receptor NK-3 | |
| UY28896A1 (es) | Formulaciones en polvo para la inhalación , las cuales contienen beta-agonistas enantioméricamente puros |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |